All In Biotech

Drug Trial Radar · NCT00548509

The Effect of Vitamin K2 on Bone Turnover

Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study

Last checked: Nov 20, 2026Latest source record: Oct 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Feb 1, 2002

Primary completion

Jan 2013

Study completion Jan 2013

Sponsor

Lead sponsor
Eisai LimitedEisai
Sponsor type
Industry
First posted
Oct 24, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 49 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To investigate the effect of menatetrenone on bone turnover in postmenopausal patients with osteoporosis. One month of menatetrenone therapy enhanced the secretion and gamma-carboxylation of osteocalcin. Moderate increases of bone resorption and formation markers were observed after 6 months. These changes may contribute to fracture prevention in patients with osteoporosis.

Conditions

  • Osteoporosis

Interventions

  • Menatetrenone (Vitamin K2)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Gamma-carboxylation

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Kumagaya-shi, Saitama, Japan

  • Site not named

    Hachioji-shi, Tokyo, Japan

  • Site not named

    Setagaya-Ku, Tokyo, Japan

  • Site not named

    Nishiyatsushiro-Gun, Yamanashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.